|
|
|
|
|
12.02.26 - 14:54
|
Alnylam Pharmaceuticals Reports Net Income In Q4 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) reported fourth quarter net income of $111.5 million compared to a loss of $83.8 million, prior year. GAAP net income per common share w......
|
|
|
|
|
|
|
|
|
|
|
29.01.26 - 14:03
|
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open.
Management will provide an update on the Company and discuss fourth quarter and year-end 2025 results as well as expectations for the future via conference call on Thursday, February 12, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. Fo...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.12.25 - 22:01
|
The Week Ahead (Dec. 22 to 28): China′s Top Legislators Meet; U.S. Tightens Biometric Entry Rules (Caixin)
|
|
|
Dec. 22 to 27: China's top legislature opens key year-end session
The Standing Committee of the 14th National People's Congress holds its session in Beijing to review draft laws including the environment code and revisions to the Foreign Trade Law. The agenda for China's top legislative body also covers the national development planning law and other legal updates.
Dec. 22: Nasdaq 100 rebalancing takes effect
The index's quarterly rebalance becomes effective, adding companies such as Alnylam Pharmaceuticals Inc. and Seagate Technology Holdings PLC. Removed constituents include Lululemon Athletica Inc. and Biogen Inc., reflecting shifts in market capitalization.
Dec. 22: Adora Cruises halts Japan trips
The Adora Magic City cruise ship cancels all call ports in Japan starting Dec.22, rerouting to South Korea amid rising bilateral tensions. The operator, Adora Cruises, becomes the first domestic cruise line to publicly halt Japan routes.
Dec. 22: Guangzhou-Zhanjiang high-speed rail line begins opera...
|
|
|
18.12.25 - 10:36
|
Alnylam plans $250m investment in Norton manufacturing facility, US (PBR)
|
|
|
This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility. The facility expansion is intended to increase capacity, lower production expenses, and enable
The post Alnylam plans $250m investment in Norton manufacturing facility, US appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
